Intestinal Cell News Volume 5.48 | Dec 20 2019

TOP STORY

Enteroendocrine and Tuft Cells Support Lgr5 Stem Cells on Paneth Cell Depletion

Researchers showed that ablation of Paneth cells in mice, using a diphtheria toxin receptor gene inserted into the P-lysozyme locus, did not affect the maintenance of Lgr5⁺ stem cells. [Proc Natl Acad Sci USA] Abstract

(Ranked by impact factor of the journal)

An In Vivo RNAi Screen Uncovers the Role of AdoR Signaling and Adenosine Deaminase in Controlling Intestinal Stem Cell Activity

Scientists demonstrated that Ras/MAPK and protein kinase A signaling act downstream of adenosine receptor (AdoR) and that Ras/MAPK mediated the major effect of AdoR on intestinal stem cell proliferation. [Proc Natl Acad Sci USA] Abstract

Thiazolides Promote G1 Cell Cycle Arrest in Colorectal Cancer Cells by Targeting the Mitochondrial Respiratory Chain

Investigators systematically investigated RM4819 and nitazoxanide in 2D and 3D colorectal cancer culture systems. Both compounds strongly inhibited proliferation of colon carcinoma cell lines by promoting G1 phase cell cycle arrest. [Oncogene] Abstract

Long Non-Coding RNA LINC00460 Silencing Represses Epithelial-Mesenchymal Transition in Colon Cancer through Downregulation of ANXA2 via Upregulating miR-433-3p

Cell proliferation, metastasis, invasion, and apoptosis were examined in vitro, and tumorigenicity was evaluated in vivo following LINC00460 silencing. Additionally, the regulatory mechanisms were investigated using LINC00460 and ANXA2 gain- or loss-of-function experiments. [Mol Ther Nucleic Acids] Abstract

The Adult Murine Intestine Is Dependent on Constitutive Laminin-γ1 Synthesis

Laminin-γ1 was required for early embryonic development; however, the need for laminin-γ1 synthesis in adulthood is unknown. A global and inducible mouse model of laminin-γ1 deficiency was generated to address this question. [Sci Rep] Full Article

Colorectal Cancers Utilize Glutamine as an Anaplerotic Substrate of the TCA Cycle In Vivo

Using orthotopic mouse colon tumors estalished from human colorectal cancer cells or patient-derived xenografts, the authors demonstrated substantial amounts of infused [¹³C₅]-glutamine enters the tricarboxylic acid (TCA) cycle in the tumors and tumors utilized anaplerotic glutamine to a greater extent than adjacent normal colon tissues. [Sci Rep] Full Article

Cholesterol‐Conjugated PEGylated PAMAM as an Efficient Nanocarrier for Plasmid Encoding Interleukin‐12 Immunogene Delivery towards Colon Cancer Cells

The features of modified polyamidoamines (PAMAMs) containing size and surface charge density, cytotoxicity and transfection efficiency were investigated in colon cancer cells. In vitro experiment showed that this modified carrier with average size of about 160 nm and zeta potential of 30 mV was able to increase the level of IL‐12 production up to two folds as compared to that of the unmodified PAMAM. [Biotechnol Prog] Abstract

Farnesol Contributes to Intestinal Epithelial Barrier Function by Enhancing Tight Junctions via the JAK/STAT3 Signaling Pathway in Differentiated Caco-2 Cells

Scientists identified that farnesol promoted intestinal barrier function, by promoting transepithelial electrical resistance, reducing paracellular flux, inducing the zonula occludens-1 protein (ZO-1) and occludin expression. [J Bioenerg Biomembr] Abstract

Loganin Alleviates LPS‐Activated Intestinal Epithelial Inflammation by Regulating TLR4/NF‐κB and JAK/STAT3 Signaling Pathways

Researchers investigated whether loganin could alleviate inflammatory bowel disease (IBD) and its mechanisms. The intestinal epithelial Caco‐2 cell line was treated with lipopolysaccharide (LPS) to establish an in vitro IBD model. [Kaohsiung J Med Sci] Abstract

Subscribe to one of our other 19 science newsletters such as Pulmonary Cell News & ESC & iPSC News.

Epigenetics/Epigenomics and Prevention by Curcumin of Early Stages of Inflammatory‐Driven Colon Cancer

The authors discuss the latest evidence in epigenetics/epigenomics alterations by curcumin in colorectal cancer (CRC) and their potential contribution in the prevention of CRC. [Mol Carcinog] Abstract

Visit our reviews page to see a complete list of reviews in the intestinal cell research field.

Qu Biologics Completes Enrollment in First Stage of Phase II Clinical Trial in Moderate to Severe Crohn’s Disease

Qu Biologics Inc. announced the completion of enrollment for the first stage of the RESTORE clinical trial, “A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO Site Specific Immunomodulators for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects with Moderate to Severe Crohn’s Disease”. [Qu Biologics Inc.] Press Release

Deciphera Pharmaceuticals Announces Submission of New Drug Application to US FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, Inc. announced the submission of a New Drug Application to the FDA for ripretinib, the company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors who have received prior treatment with imatinib, sunitinib and regorafenib. [Deciphera Pharmaceuticals, Inc.] Press Release

US FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI^® (Encorafenib) in Combination with ERBITUX^® (Cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAF^V600E-Mutant Metastatic Colorectal Cancer after Prior Therapy

Pfizer, Inc. announced that the FDA has accepted and granted priority review to the Company’s supplemental New Drug Application (sNDA) for BRAFTOVI^® in combination with ERBITUX^® based on results from the Phase III BEACON CRC trial, which evaluated the efficacy and safety of BRAFTOVI in combination with ERBITUX with or without MEKTOVI^® in patients with advanced BRAF^V600E-mutant metastatic colorectal cancer, following one or two lines of therapy. [Pfizer, Inc. (Business Wire, Inc)] Press Release

2020 US Spending Bill Restricts Some Animal Research, Pushes for Lab Animal Retirement

Federal research agencies will be under increased pressure to reduce their use of monkeys, dogs, and cats when President Donald Trump signs the final 2020 US spending bill. [ScienceInsider] Editorial

Trump Picks Computer Scientist to Lead National Science Foundation

US President Donald Trump has nominated Sethuraman Panchanathan, a computer scientist researcher and vice-president at Arizona State University in Tempe, to be the next head of the National Science Foundation. [Nature News] Editorial

NEW The Evolving Landscape of Cancer Modeling
March 2-5, 2020
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Faculty Scientist Position – IBD Research (The University of Texas Health Science Center at Houston)

NEW Postdoctoral Research Fellow – Tumor Microenvironment (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher(s) – Intestinal Bacteria (University of Helsinki)

Researcher – Synthetic Ecology of Human Gut Microbiota (Flanders Institute for Biotechnology)

Assistant Professor – Intestinal Microbiota and Immunity (Hokkaido University)

Research Position – Microscopy of Human Tumors (Vienna University of Technology)

Postdoctoral Researcher – Mucosal Immunology (KU Leuven)

Postdoctoral Fellow – Neonatal Microbiota on Immune Imprinting (Pasteur Institute)

Research Scientist – In Vivo Research on Wnt Signaling in Self-Renewel (Surrozen)

Principal Researcher – Systems Disease Biology (Boehringer Ingelheim)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Intestinal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.